Movano (MOVE) 10-Q 14 May 21 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 13, 2021
Document Information Line Items
Entity Registrant Name	Movano Inc.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		32,772,060
Amendment Flag	false
Entity Central Index Key	0001734750
Entity Current Reporting Status	No
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Entity File Number	001-40254
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 46,754	$ 5,710
Payroll tax credit, current portion	479	500
Prepaid expenses and other current assets	1,919	691
Total current assets	49,152	6,901
Property and equipment, net	48	38
Payroll tax credit, noncurrent portion	155	134
Other assets	56	10
Total assets	49,411	7,083
Current liabilities:
Accounts payable	375	246
Paycheck Protection Program loan, current portion	323	248
Other current liabilities	974	666
Total current liabilities	1,672	1,160
Noncurrent liabilities:
Convertible promissory notes, net		11,342
Accrued interest		292
Paycheck Protection Program loan, noncurrent portion	28	103
Warrant liability		1,549
Derivative liability		121
Early exercised stock option liability	406	417
Other noncurrent liabilities	23	161
Total noncurrent liabilities	457	13,985
Total liabilities	2,129	15,145
Commitments and contingencies (Note 11)
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value, 5,000,000 and no shares authorized at March 31, 2021 and December 31, 2020; no shares issued and outstanding at March 31, 2021 and December 31, 2020
Common stock, $0.0001 par value, 75,000,000 and 22,069,652 shares authorized at March 31, 2021 and December 31, 2020; 32,772,060 and 6,393,069 shares issued and outstanding at March 31, 2021 and December 31, 2020	3	1
Additional paid-in capital	95,882
Accumulated deficit	(48,603)	(40,881)
Total stockholders’ equity (deficit)	47,282	(40,880)
Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit)	49,411	7,083
Series A Redeemable Convertible Preferred Stock
Noncurrent liabilities:
Preferred stock value		13,856
Series B Redeemable Convertible Preferred Stock
Noncurrent liabilities:
Preferred stock value		$ 18,962

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, shares par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	75,000,000	22,069,652
Common stock, shares issued	32,772,060	6,393,069
Common stock, shares outstanding	32,772,060	6,393,069
Series A Redeemable Convertible Preferred Stock
Preferred stock, shares par value (in Dollars)	$ 0.1	$ 0.1
Preferred stock, shares authorized		2,692,253
Preferred stock, shares issued		2,692,253
Preferred stock, shares outstanding		2,692,253
Preferred stock, shares ,liquidation preference (in Dollars per share)	$ 0	$ 15,170
Series B Redeemable Convertible Preferred Stock
Preferred stock, shares par value (in Dollars)	$ 0.1	$ 0.1
Preferred stock, shares authorized		5,238,095
Preferred stock, shares issued		4,942,319
Preferred stock, shares outstanding		4,942,319
Preferred stock, shares ,liquidation preference (in Dollars per share)	$ 0	$ 21,858

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
OPERATING EXPENSES:
Research and development	$ 1,942	$ 1,501
General and administrative	1,324	518
Total operating expenses	3,266	2,019
Loss from operations	(3,266)	(2,019)
Other income (expense), net:
Interest expense	(883)	(8)
Change in fair value of warrant liability	(1,581)	23
Change in fair value of derivative liability	121	(33)
Interest and other income, net	1	12
Other income (expense), net	(2,342)	(6)
Net loss and comprehensive loss	(5,608)	(2,025)
Accretion and dividends on redeemable convertible preferred stock	(2,489)	(1,956)
Net loss attributable to common stockholders	$ (8,097)	$ (3,981)
Net loss per share attributable to common stockholders, basic and diluted (in Dollars per share)	$ (1.01)	$ (1.58)
Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in Shares)	8,049,048	2,524,209

Condensed Statements of Redeema

Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Unaudited) (Deficit) - USD ($) $ in Thousands	Series A Redeemable Convertible Preferred Stock	Series B Redeemable Convertible Preferred Stock	Common Stock	Accumulated Deficit	Additional Paid-In Capital	Total
Balance at Dec. 31, 2019	$ 11,212	$ 12,692		$ (19,907)		$ (19,907)
Balance (in Shares) at Dec. 31, 2019	2,692,253	4,942,319	4,539,584
Stock-based compensation					$ 49	49
Accretion of Series A and Series B redeemable convertible preferred stock	$ 609	$ 1,347			(1,956)	(1,956)
Reclassification of negative additional paid-in capital to accumulated deficit				(1,907)	1,907
Net loss				(2,025)		(2,025)
Balance at Mar. 31, 2020	$ 11,821	$ 14,039		(23,839)		(23,839)
Balance (in Shares) at Mar. 31, 2020	2,692,253	4,942,319	4,539,584
Balance at Dec. 31, 2020	$ 13,856	$ 18,962	$ 1	(40,881)		(40,880)
Balance (in Shares) at Dec. 31, 2020	2,692,253	4,942,319	6,393,069
Stock-based compensation					355	355
Accretion of Series A and Series B redeemable convertible preferred stock	$ 686	$ 1,803			(2,489)	(2,489)
Issuance of common stock upon exercise of options					49	49
Issuance of common stock upon exercise of options (in Shares)			134,541
Vesting of early exercised stock options					38	38
Reclassification of negative additional paid-in capital				(2,114)	2,114
Conversion of preferred stock to common stock upon initial public offering	$ (14,542)	$ (20,765)	$ 1		35,306	35,307
Conversion of preferred stock to common stock upon initial public offering (in Shares)	(2,692,253)	(4,942,319)	11,436,956
Issuance of common stock upon initial public offering, net of issuance costs			$ 1		41,924	41,925
Issuance of common stock upon initial public offering, net of issuance costs (in Shares)			9,775,000
Issuance of underwriter warrants upon initial public offering					2,349	2,349
Reclassification of liability-classified warrants upon initial public offering					3,130	3,130
Conversion of convertible promissory notes and accrued interest upon initial public offering					12,550	12,550
Conversion of convertible promissory notes and accrued interest upon initial public offering (in Shares)			5,015,494
Issuance of common stock for nonemployee services					85	85
Issuance of common stock for nonemployee services (in Shares)			17,000
Beneficial conversion feature upon issuance of convertible promissory note					471	471
Net loss				(5,608)		(5,608)
Balance at Mar. 31, 2021			$ 3	$ (48,603)	$ 95,882	$ 47,282
Balance (in Shares) at Mar. 31, 2021			32,772,060

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (5,608)	$ (2,025)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1	3
Stock-based compensation	355	49
Accretion of debt discount on convertible promissory notes	772	5
Accrued interest on convertible promissory notes	115	5
Nonemployee services under convertible promissory notes	50
Compensation of nonemployee services upon issuance of common stock	74
Change in fair value of derivative liability	(121)	32
Change in fair value of warrant liability	1,581	(23)
Changes in operating assets and liabilities:
Payroll tax credit		(165)
Prepaid expenses and other current assets	(1,425)	(73)
Other assets	(46)	165
Accounts payable	125	231
Other current liabilities	87	(427)
Net cash used in operating activities	(4,040)	(2,223)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(11)
Net cash used in investing activities	(11)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible promissory notes		1,260
Payment of issuance costs		(35)
Issuance of common stock	76
Proceeds from issuance of shares upon Initial Public Offering - net of issuance costs	45,019
Net cash provided by financing activities	45,095	1,225
Net increase in cash and cash equivalents	41,044	(998)
Cash and cash equivalents at beginning of period	5,710	4,291
Cash and cash equivalents at end of period	46,754	3,293
NONCASH INVESTING AND FINANCING ACTIVITIES:
Accretion of Series A redeemable convertible preferred stock	686	609
Accretion of Series B redeemable convertible preferred stock	1,803	1,347
Conversion of preferred stock to common stock upon initial public offering	35,307
Reclassification of liability-classified warrants upon initial public offering	3,130
Issuance of underwriter warrants upon initial public offering	2,349
Issuance of convertible promissory notes upon completion of nonemployee services	500
Beneficial conversion feature upon issuance of convertible promissory note	471
Conversion of convertible promissory notes and accrued interest upon initial public offering	12,550
Vesting of common stock issued upon early exercise	38
Issuance of common stock for nonemployee services	11
Reclassification of deferred offering costs upon initial public offering	497
Initial public offering expenses in accrued expenses	244
Initial public offering expenses in accounts payable	$ 4

Business Organization, Nature o

Business Organization, Nature of Operations	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
BUSINESS ORGANIZATION, NATURE OF OPERATIONS	Note 1 – Business Organization, Nature of Operations Movano Inc. (the “Company” or “Movano” or “Our”) was incorporated in Delaware on January 30, 2018 as Maestro Sensors Inc. and changed its name to Movano Inc. on August 3, 2018. The Company is in the development-stage and is a health-focused technology company creating simple, smart, and personalized wearables designed to help individuals on their health journey optimize for good health today and to help prevent and manage chronic diseases in the future. The Company’s wearables are being developed to provide vital health information, including glucose and blood pressure data, in a variety of form factors to meet individual style needs and give users actionable feedback to improve the quality of their lives. Since inception, the Company has engaged in only limited research and development of product candidates and underlying technology. As of December 31, 2020, the Company had not yet completed the development of its product and had not yet recorded any revenues. From February 2020 to December 2020, the Company issued subordinated convertible promissory notes for approximately $11.1 million in net proceeds (See Note 6). Additionally, in May 2020, the Company received a Paycheck Protection Program loan for $0.4 million (See Note 5.) In December 2019, a novel coronavirus and the resulting disease (“COVID-19”) was reported, and in January 2020, the World Health Organization (“WHO”) declared it a Public Health Emergency of International Concern. In February 2020, the WHO raised its assessment of the COVID-19 threat from high to very high at a global level due to the continued increase in the number of cases and affected countries, and in March 2020, the WHO characterized COVID-19 as a pandemic. The Company is continuing to ascertain the long-term impact of the COVID-19 pandemic on its business, but given the uncertainty about the situation, the Company cannot estimate the impact to our financial statements from the economic crisis arising from COVID-19. The Company’s Registration Statement on Form S-1, as amended (Reg. No. 333-252671), was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on March 23, 2021. The registration statement registered the securities offered in the Company’s initial public offering (“IPO”). In the IPO, the Company sold 9,775,000 shares of common stock at a price to the public of $5.00 per share, including the full exercise of the underwriters’ option to purchase additional shares. The IPO closed on March 25, 2021 and the underwriters exercised their overallotment option as of March 25, 2021, as a result of which the Company raised net proceeds of $44.3 million after deducting $3.3 million in underwriting discounts, commissions, and expenses and $1.3 million in offering expenses paid or payable by the Company. National Securities Corporation (“NSC”) was the underwriter for the IPO, and also received a warrant related to the IPO, which is discussed in Note 9. No portion of the net proceeds from the IPO were used for payments made by the Company to its directors or officers or persons owning ten percent or more of its common stock or to their associates, or to the Company’s affiliates, other than payments in the ordinary course of business to officers for salaries and to nonemployee directors as compensation for board or board committee service. The Company has incurred losses from operations and has generated negative cash flows from operating activities since inception. The Company expects to continue to incur net losses for the foreseeable future as it continues the development of its technology. The Company’s ultimate success depends on the outcome of its research and development and commercialization activities, for which it expects to incur additional losses in the future. Through March 31, 2021, the Company has relied primarily on the proceeds from equity offerings to finance its operations. The Company expects to require additional financing to fund its future planned operations, including research and development and commercialization of its products. The Company will likely raise additional capital through the issuance of equity, borrowings, or strategic alliances with partner companies. However, if such financing is not available at adequate levels, the Company would need to reevaluate its operating plans.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements include the accounts of the Company and have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. The unaudited and condensed financial statements have been prepared on the same basis as the annual financial statements. In the opinion of management, the accompanying unaudited and condensed financial statements reflect all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021. The condensed balance sheet as of December 31, 2020 has been derived from audited financial statements at that date but does not include all the information required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and notes thereto for the preceding fiscal year included in Amendment No. 2 to the Company’s Registration Statement on Form S-1 filed with the SEC on March 17, 2021. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock, stock options and warrants, the valuation of the embedded redemption derivative liability and income taxes. Estimates are periodically reviewed considering changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment. The Company’s chief operating decision maker is the chief executive officer. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Concentrations of Credit Risk and Off-Balance Sheet Risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. All cash and cash equivalents are held in United States financial institutions. Cash equivalents consist of interest-bearing money market accounts. The amounts deposited in the money market accounts exceeds federally insured limits. The Company has not experienced any losses related to this account and believes the associated credit risk to be minimal due to the financial condition of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets were comprised of prepaid expenses, other current receivables, and deferred offering costs, which consist of legal, accounting, filing and other fees related to the IPO that were capitalized prior to the IPO. The deferred offering costs were offset against proceeds from the IPO upon the effectiveness of the IPO within additional paid-in capital. As of March 31, 2021 and December 31, 2020, offering costs of approximately $0 and $0.5 million were capitalized, respectively. Paycheck Protection Program Loan The Company accounts for funds received from the Paycheck Protection Program as a financial liability with interest accrued and expensed over the term of the loan under the effective interest method. The loan will remain recorded as a liability until the Company has been legally released from the liability or the Company repays the liability. Any amount that is ultimately forgiven by the lender would be recognized in the statement of operations and comprehensive loss as a gain extinguishment. Convertible Financial Instruments The Company bifurcates embedded redemption and conversion options from their host instruments and accounts for them as freestanding derivative financial instruments at fair value if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Debt discounts under these arrangements are amortized to interest expense using the interest method over the earlier of the term of the related debt or their earliest date of redemption. From time to time, the Company issues convertible financial instruments to nonemployees in payment for services that are provided. Until the services are completely rendered, the Company will expense the principal and any interest earned prior to the service completion to the representative expense account for the services performed and will record a noncurrent liability for the expected amount of the principal balance. Upon completion of the services, the Company will reclassify the noncurrent liability balance to the balance of an outstanding convertible financial instrument and assess the embedded redemption and conversion options that are applicable at that time. Beneficial Conversion Feature If the conversion feature of conventional convertible promissory notes provides for a rate of conversion that is below market value, this feature is characterized as a beneficial conversion feature (“BCF”). A BCF is recorded by the Company as a debt discount and as additional paid-in capital on the condensed balance sheet. In those circumstances, the convertible debt is recorded net of the discount related to the BCF and the Company amortizes the discount to interest expense over the life of the debt using the effective interest method. Redeemable Convertible Preferred Stock The Company records all shares of redeemable convertible preferred stock at their respective issuance price less issuance costs on the dates of issuance. Under certain circumstances the Company will be required to redeem the Series A and Series B redeemable convertible preferred stock unless an IPO has been consummated prior to April 1, 2021, or an extension or waiver is obtained upon approval of a majority of the holders of such preferred stock. As the preferred stock becomes redeemable due to the passage of time, the Company considers the preferred stock to be redeemable as of April 1, 2021. The Company records the accretion of the Series A and B preferred stock balances to their respective redemption amounts using the effective interest method. The redeemable convertible preferred stock is presented outside of stockholders’ deficit on the condensed balance sheet as of December 31, 2020. Upon the IPO, the redeemable convertible preferred stock converted in to 11,436,956 shares of common stock. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. As the Company maintained a full valuation allowance against its deferred tax assets, the changes resulted in no provision or benefit from income taxes during the three months ended March 31, 2021 and 2020. The Company accounts for unrecognized tax benefits using a more-likely-than-not threshold for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. The Company establishes a liability for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. The Company records an income tax liability, if any, for the difference between the benefit recognized and measured and the tax position taken or expected to be taken on the Company’s tax returns. To the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The liability is adjusted considering changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of liability provisions and changes to the liability that are considered appropriate. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. Stock-Based Compensation The Company measures equity classified stock-based awards granted to employees, directors, and nonemployees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term, the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company accounts for forfeitures as they occur. Early Exercised Stock Option Liability Upon the early exercise of stock options by employees, the Company records as a liability the purchase price of unvested common stock that the Company has a right to repurchase if and when the employment of the stockholder terminates before the end of the requisite service period. The proceeds originally recorded as a liability are reclassified to additional paid-in capital as the Company’s repurchase right lapses. Fair Value Measurements The Company accounts for certain of its financial assets and liabilities at fair value. The Company uses a three-level hierarchy, which prioritizes, within the measurement of fair value, the use of market-based information over entity-specific information for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date. Fair value focuses on an exit price and is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The inputs or methodology used for valuing financial instruments are not necessarily an indication of the risk associated with investing in those financial instruments. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Level 3 Significant unobservable inputs that cannot be corroborated by market data. The following tables provide a summary of the assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands). March 31, 2021 Fair Value Level 1 Level 2 Level 3 Assets – money market funds $ 46,328 $ 46,328 $ — $ — December 31, 2020 Fair Value Level 1 Level 2 Level 3 Assets – money market funds $ 5,181 $ 5,181 $ — $ — Warrant liability $ 1,549 $ — $ — $ 1,549 Derivative liability $ 121 $ — $ — $ 121 The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. At December 31, 2020, the warrants related to the Series A preferred stock issuance, the Series B preferred stock issuance, and the convertible promissory notes and the derivative liability related to the issuance of convertible promissory notes are classified within level 3 of the valuation hierarchy. The instruments are not present at March 31, 2021 in light of accounting ramifications of the IPO, which are discussed further in Note 6 and Note 9. The carrying amounts of cash and cash equivalents, prepaid expenses, payroll tax credit, accounts payable and accrued liabilities approximate fair value due to the short-term nature of these instruments. Based upon interest rates currently available to the Company for debt with similar terms, the carrying values of the Company’s convertible promissory notes and Paycheck Protection Program Loan are approximately equal to their fair values. Net Loss per Share Attributable to Common Stockholders Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. The net loss attributable to common stockholders is calculated by adjusting the net loss of the Company for the accretion on the Series A and B redeemable convertible preferred stock and cumulative dividends on Series A and B redeemable convertible preferred stock. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since the effects of potentially dilutive securities are antidilutive. Recently Adopted Accounting Pronouncements In December 2019, the FASB issued Accounting Standards Update 2019-12, Income Taxes (Topic 740 In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	Note 3 – Property and Equipment Property and equipment, net, as of March 31, 2021 and December 31, 2020, consisted of the following (in thousands): March 31, December 31, 2021 2020 Office equipment and furniture $ 43 $ 43 Test equipment 33 22 Total property and equipment 76 65 Less: accumulated depreciation (28 ) (27 ) Total property and equipment, net $ 48 $ 38 Total depreciation expense related to property and equipment was approximately $1,000 and $3,000 for the three months ended March 31, 2021 and 2020, respectively.

Other Current Liabilities

Other Current Liabilities	3 Months Ended
	Mar. 31, 2021
Other Current Liabilities [Abstract]
OTHER CURRENT LIABILITIES	Note 4 – Other Current Liabilities Other current liabilities as of March 31, 2021 and December 31, 2020 consisted of the following (in thousands): March 31, December 31, 2021 2020 Accrued research and development $ — $ 197 Accrued compensation 380 184 Accrued vacation 218 192 Accrued legal expense 85 41 Accrued accounting and consulting expense 228 40 Other 63 12 $ 974 $ 666

Paycheck Protection Program Loa

Paycheck Protection Program Loan	3 Months Ended
	Mar. 31, 2021
Paycheck Protection Program Loan [Abstract]
PAYCHECK PROTECTION PROGRAM LOAN	NOTE 5 – PAYCHECK PROTECTION PROGRAM LOAN The Paycheck Protection Program (“PPP”) was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration (“SBA”). On April 23, 2020, the Company entered into a promissory note with Silicon Valley Bank evidencing an unsecured loan in the aggregate amount of approximately $351,000 under the PPP (the “PPP Loan”). The interest rate on the PPP Loan was 1.00% and the term was two years, with a deferral of payments for ten months from the date of origination. On May 7, 2020, the Company elected to repay the PPP loan in full until further guidance was provided by the SBA on the loan origination and eligibility requirements. On May 27, 2020, the Company entered into a promissory note with Silicon Valley Bank evidencing an unsecured loan in the aggregate amount of approximately $351,000, with all other terms the same as the prior loan. Beginning eleven months from the date of the PPP Loan, the Company is required to make monthly payments of principal and interest. The promissory note evidencing the PPP Loan contains customary events of default relating to, among other things, payment defaults or breaching the terms of the PPP Loan documents. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts owing from the Company, or filing suit and obtaining judgment against the Company. The PPP Loan may be repaid at any time by the Company without prepayment penalties. Funds from the PPP Loan may only be used for payroll costs, costs used to continue group health care benefits, mortgage payments, rent, utilities, and interest on other debt obligations, if those debt obligations are incurred before February 15, 2020. The Company intends to use the entire PPP Loan amount for qualifying expenses. Under the terms of the CARES Act, PPP loan recipients can apply for and be granted forgiveness for all or a portion of the loan granted under the PPP. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for qualifying expenses. No assurance is provided that the Company will obtain forgiveness of the PPP Loan in whole or in part. As of March 31, 2021, future minimum payments under the PPP loan are as follows: $323,000 in 2021; and $28,000 in 2022.

Convertible Promissory Notes

Convertible Promissory Notes	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
CONVERTIBLE PROMISSORY NOTES	NOTE 6 – CONVERTIBLE PROMISSORY NOTES On various dates between February 2020 and December 2020, the Company received total proceeds of approximately $11.8 million from the issuance of subordinated convertible promissory notes (“Convertible Notes”) to investors. The Convertible Notes accrued interest at 4% per year and the principal balance of the Convertible Notes, plus all accrued interest is due on February 28, 2022 (the Maturity Date). The Convertible Notes were convertible upon the occurrence of certain events, including upon a change in control or a next equity financing. The conversion features are described as follows: Conversion Event Description Conversion Price Automatic Conversion – Next Qualified Equity Financing Upon the closing of a Next Qualified Equity Financing (defined as greater than $5,000,000), the Convertible Notes are converted into shares issued equal to the outstanding balance divided by the Conversion Price An amount equal to the lower of (i) 80% of the lowest per-share selling price of such stock sold by the Company at the Next Qualified Equity Financing or (ii) the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents (defined as fully diluted common shares for all outstanding securities, excluding common shares reserved for issuance or exercise of options or grants in the future) immediately prior to Next Financing Closing Automatic Conversion – Change of Control (defined as consolidation or merger of the Company or transfer of a majority of share ownership or disposition of substantially all assets of the Company) If at any time before payment or conversion of the balance, the Company effects a Change of Control, all of the balance outstanding immediately prior to such Change of Control will automatically convert into the most senior series of Preferred Stock outstanding immediately prior to such Change of Control at the Conversion Price. An amount equal to the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to such Change of Control. Automatic Conversion – Maturity Date If the Company has not paid or otherwise converted the entire balance before the Maturity Date, then on the Maturity Date, all of the balance then outstanding will automatically convert into the most senior series of Preferred Stock outstanding as of the Maturity Date at the Conversion Price then in effect. An amount equal to the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents as of the Maturity Date. Automatic Conversion – IPO If at any time before payment or conversion of the balance, the Company consummates an IPO, all of the balance outstanding immediately prior to the IPO will automatically convert into Common Stock at the Conversion Price. An amount equal to the lower of (i) 80% of the lowest per-share selling price of the common stock sold by the Company in an IPO or (ii) the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to closing of an IPO. Conversion Event Description Conversion Price Optional Conversion If at any time while the Convertible Notes are still outstanding the Company sells stock in a single transaction or in a series of related transactions that does not constitute a Next Qualified Equity Financing (and thus is defined as a Non-qualified Financing), then, at the closing of the Nonqualified Financing, the balance then outstanding may be converted, at the option of the holder, into that number of shares of Non-qualified Preferred Stock (preferred stock sold in the Non-qualified Financing) determined by dividing (i) the balance by (ii) the Conversion Price then in effect. An amount equal to the lowest per share selling price of Nonqualified Preferred Stock sold by the Company for new cash investment in the Non-Qualified Financing. As part of the Convertible Note financing, the Company agreed to issue subordinated convertible promissory notes to nonemployees in exchange for services totaling $747,000. As of December 31, 2020, Convertible Notes totaling approximately $247,000 were issued to nonemployees in exchange for services. As of December 31, 2020, future services of $500,000 of the original $747,000 had not been fully completed. A portion of those services that had been completed were recorded as a component of other noncurrent liabilities of $150,000 on the condensed balance sheet at December 31, 2020. During the three months ended March 31, 2021, additional nonemployee services of $50,000 were completed, which were recorded as a component of other noncurrent liabilities. In connection with the IPO, a Convertible Note for $500,000 was issued for nonemployee services and the $300,000 of the nonemployee services that remained to be completed was recorded in prepaid assets and other current expenses on the condensed balance sheet. The Company calculated a BCF of approximately $0.5 million upon the issuance of this Convertible Note. During the three months ended March 31, 2020, there were no nonemployee services completed. In connection with the Convertible Notes, the Company issued 10,000 and 204,500 warrants to purchase common stock, to a noteholder and its brokers, respectively. The warrants have a five-year life and are initially exercisable into common stock at $2.97 per share. (See Note 9 – Common Stock Warrants for fair value computation and discussion of the change in the exercise price). During March 2021, 42,220 of these warrants to purchase common stock were cancelled. Issuance costs and commissions to brokers to obtain the Convertible Notes were recorded as a debt discount in the amount of approximately $83,000 and $612,000, respectively. The Company determined that the terms that would result in Convertible Notes automatically converting at (i) 80% of the lowest per-share selling price of the stock sold by the Company in the Next Qualified Equity Financing or (ii) 80% of the lowest per-share selling price of the Conversion Stock sold by the Company in an IPO are deemed a redemption feature. The Company also concluded that those redemption features require bifurcation from the Convertible Notes and subsequent accounting in the same manner as a freestanding derivative. Accordingly, subsequent changes in the fair value of these redemption features are measured at each reporting period and recognized in the condensed statement of operations and comprehensive loss. The sum of the fair value of the warrants, the fair value of the embedded redemption derivative liability, issuance costs, BCF and commission payments for the Convertible Notes were recorded as debt discounts to be amortized to interest expense over the respective term using the effective interest method. During the three months ended March 31, 2021 and 2020, the Company recognized interest expense of approximately $0.8 million and $0 from the accretion of those debt discounts. The Convertible Notes automatically converted upon the closing of the IPO at the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to the closing of the IPO. The outstanding principal ($12.5 million) and interest due ($0.4 million) under the Convertible Notes, in an aggregate amount of $12.9 million, was converted into 5,015,494 shares of the Company’s common stock at the implied per share conversion of $2.5736. The carrying value of the Convertible Notes was credited to common stock and additional paid-in capital on the condensed balance sheet. The remaining unamortized discount of $0.4 million was recorded to additional paid-in capital and no gain or loss was recognized on the conversion. The remaining unamortized discount related to the BCF of $0.5 million was recognized immediately as interest expense in the condensed statement of operations and comprehensive loss. Derivative Liability As described above, the redemption provisions embedded in the Convertible Notes required bifurcation and measurement at fair value as a derivative. The fair value of the Convertible Note embedded redemption derivative liability was calculated by determining the value of the debt component of the Convertible Notes at various conversion or maturity dates using a Probability Weighted Expected Return valuation method. The fair value calculation placed greater probability on the occurrence of the conversion or the maturity date scenario, with little or no weight given to other scenarios. The fair value of the embedded redemption derivative liability is significantly influenced by the discount rate, the remaining term to maturity and the Company’s assumptions related to the probability of a qualified financing or no financing prior to maturity. The Financing Date is the estimated date of an automatic conversion as the result of a Next Qualified Equity Financing or an IPO. The Company estimated the fair value of the embedded redemption derivative liability using the following weighed average assumptions as of December 31, 2020: Financing Date Maturity Date Probability of Conversion at Financing 80% 20% Expected Term March 2021 February 2022 Conversion Ratio 1.25 N/A Discount Rate 1.68% to 11.67% N/A The Company estimated the fair value of the embedded redemption derivative liability using the following weighed average assumptions as of March 31, 2020: Financing Date Maturity Date Probability of Conversion at Financing 80% 20% Expected Term March 2021 February 2022 Conversion Ratio 1.25 N/A Discount Rate 6.18% to 11.67% N/A The embedded redemption derivative liability no longer had significant value as of the date of the Company’s IPO since the conversion of the Convertible Notes occurred via a redemption feature that was not bifurcated as a derivative. Upon the conversion of the Convertible Notes at the IPO, the Company recorded a final change in the fair value of the derivative liability of $0.1 million in the condensed statement of operations and comprehensive loss, and the derivative liability was extinguished. The changes in the fair value of the derivative liability for the three months ended March 31, 2021 and 2020 were as follows: Warrant Issuance December 31, Fair Value at Change in March 31, Derivative liability $ 121 — (121 ) $ — Warrant Issuance December 31, Fair Value at Change in March 31, Derivative liability $ — 71 32 $ 103

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	3 Months Ended
	Mar. 31, 2021
Redeemable Convertible Preferred Stock Disclosure [Abstract]
REDEEMABLE CONVERTIBLE PREFERRED STOCK	Note 7 – REDEEMABLE Convertible Preferred Stock On March 28, 2019, the Company’s Second Amended and Restated Certificate of Incorporation was filed with the Delaware Secretary of State which (i) increased the number of shares of common stock the Company is authorized to issue to 22,069,652; (ii) increased the number of shares of preferred stock the Company was authorized to issue to 7,930,348, of which 2,692,253 shares were designated as Series A preferred stock and 5,238,095 shares were designated as Series B preferred stock; (iii) amended and set a fixed conversion price of Series A preferred stock to $1.40; and (iv) extended the IPO Commitment Date from April 1, 2020 to no later than March 31, 2021. The Company assessed the accounting treatment of the amendment of the Certificate of Incorporation related to the Series A preferred stock and determined that the amendment is a modification for accounting purposes. After considering the nature of the changes as a result of the amendment, the Company determined the modification of the Series A preferred stock did not have a significant impact on the financial statements. On various dates from March 2019 through August 2019, the Company issued 4,942,319 shares of Series B preferred stock at $2.10 per share for net cash proceeds of $9.3 million. The Series B preferred stock has a liquidation preference of an amount equal to the greater of (i) two times the original issue price of $2.10 per share (adjusted for stock splits, stock dividends, stock combination, recapitalizations and certain similar events) plus any declared and unpaid dividends thereon or (ii) the amount per share that would have been received by the holders had the Series B preferred stock been converted into common stock immediately prior to such liquidation, dissolution or winding-up plus any declared and unpaid dividends thereon, pari passu with the Series A preferred stock and in preference to any distributions to the holders of common stock. The Series B preferred stock was measured and recorded at the transaction price net of issuance costs, resulting in an initial value of $9.3 million. The accretion to the carrying value of the Series B preferred stock was recorded as a charge to additional paid in capital. The accumulated accretion as of the IPO date was $11.5 million, which resulted in an adjusted Series B preferred stock carrying value of $20.8 million. The accretion to the carrying value of the Series A preferred stock was recorded as a charge to additional paid in capital. The accumulated accretion as of the IPO date was $8.2 million, which resulted in an adjusted Series A preferred stock carrying value of $14.5 million. Upon the IPO, the redeemable convertible preferred stock converted in to 11,436,956 shares of common stock and no shares of redeemable convertible preferred stock remain outstanding as of March 31, 2021. On March 24, 2021, the Company’s Third Amended and Restated Certificate of Incorporation was filed with the Delaware Secretary of State which (i) eliminated the Company’s Series A and Series B preferred stock, (ii) increased the authorized number of shares of common stock to 75,000,000 and (iii) authorized 5,000,000 shares of preferred stock at par value of $0.0001 per share. The significant rights and preferences of the preferred stock will be established by the Company’s Board of Directors (the “Board”) upon issuance of any such series of preferred stock in the future.

Common Stock

Common Stock	3 Months Ended
	Mar. 31, 2021
Stockholders' Equity Note [Abstract]
COMMON STOCK	Note 8 – Common Stock As of March 31, 2021 and December 31, 2020, the Company was authorized to issue 75,000,000 and 22,069,652 shares of common stock with a par value of $0.0001 per share, and 32,772,060 and 6,393,069 shares were issued and outstanding, respectively. Conversion of Redeemable Convertible Preferred Stock In connection with the closing of the IPO, on March 25, 2021, the outstanding shares of the Company’s Series A and Series B redeemable convertible preferred stock was converted into 11,436,956 shares of the Company’s common stock. The holders of the common stock with respect to the conversion shares are subject to lock-up requirements with respect to the conversion shares until September 25, 2021. Conversion of Convertible Notes In connection with the funding of the IPO, on March 25, 2021, the principal and interest due under the Company’s Convertible Notes, in an aggregate amount of $12.9 million, was converted into 5,015,494 shares of the Company’s common stock. The purchasers of the convertible notes are subject to lock-up requirements with respect to the conversion shares until September 25, 2021. Third Amended and Restated Certificate of Incorporation In connection with the IPO, the Third Amended and Restated Certificate of Incorporation became effective and authorized 75,000,000 shares of common stock at par value of $0.0001 per share. Dividends may be declared and paid on the common stock when and if determined by the Board of Directors. Upon liquidation, each common stockholder is entitled to receive an equal portion of the distribution. Each holder of common stock will have one vote in respect of each share of common stock held. The rights and privileges listed above will be subject to preferential rights of any then outstanding shares of preferred stock. At the IPO date, the Company issued 17,000 shares of common stock for nonemployee services valued at $85,000. Common stock reserved for future issuance as March 31, 2021 is summarized as follows: Warrants to purchase common stock 1,938,143 Stock options outstanding 4,367,637 Stock options available for future grants 1,340,322 Total 7,646,102 Restricted Stock Purchase Agreements In 2018, 400,000 shares were issued to the Company’s founder at inception pursuant to a Restricted Stock Purchase Agreement. The Restricted Stock Purchase Agreement stipulates that in the event of the voluntary or involuntary termination of the Company’s founder’s continuous service status for any reason (including death or disability), with or without cause, the Company or its assignees(s) shall have an option (“Repurchase Option”) to repurchase all or any portion of the shares held by the Purchaser as of the termination date which have not yet been released from the Company’s Repurchase Option at the original purchase price of $0.0125 per share. Shares are to be released from the Repurchase Option over four years. The initial 12/48ths of the shares were released on January 30, 2019, and an additional 1/48th of the shares are being released monthly thereafter. As of March 31, 2021 and December 31, 2020, 83,333 and 108,333 of the shares issued to the Company’s founder remain subject to the Repurchase Option, respectively. These shares were originally purchased by the Company’s founder at $0.0125 per share. In 2018, 3,640,000 shares were also issued pursuant to a Restricted Stock Purchase Agreement. The holders of these shares are considered related parties of the Company because the holders are directly related either to the founder or to the legal counsel of the Company. The same terms described above apply to these issuances. As of March 31, 2021 and December 31, 2020, 758,334 and 985,834 of the shares issued to these holders remain subject to the Repurchase Option, respectively. These shares were originally purchased by the holders at $0.0125 per share. Early Exercised Stock Option Liability During the three months ended March 31, 2021, 50,000 shares were issued upon the early exercise of common stock options. The Exercise Notice (Early Exercise) Agreement states that the Company has the option to repurchase all or a portion of the unvested shares in the event of the separation of the holder from service to the Company. The shares continue to vest in accordance with the original vesting schedules of the former option agreements. There were no early exercises during the three months ended March 31, 2020. As of March 31, 2021 and December 31, 2020, the Company has recorded a repurchase liability for approximately $406,000 and $417,000 for 826,127 and 856,814 shares that remain unvested. The weighted average remaining vesting period is approximately 3 years.

Common Stock Warrants

Common Stock Warrants	3 Months Ended
	Mar. 31, 2021
Disclosure Text Block Supplement [Abstract]
COMMON STOCK WARRANTS	Note 9 – Common Stock Warrants Preferred A Placement Warrants On February 22, 2018, the Company entered into an agreement with NSC, pursuant to which the Company engaged NSC as the Company’s exclusive financial advisor and placement agent in connection with an offering or series of offerings of Company securities. Specifically, NSC was the placement agent in connection with the sale of its Series A preferred stock. In connection with the closing of Series A preferred stock offering, the Company issued warrants (“Preferred A Placement Warrants”) to purchase a total of 133,648 shares of its common stock to NSC on March 14, 2018 and April 23, 2018. On June 1, 2018, the Preferred A Placement Warrants were reassigned among NSC and three individuals at LPV. The Preferred A Placement Warrants have a term of five years and the exercise price is equal to the conversion price of Series A preferred stock upon its conversion. The Preferred A Placement Warrants included an adjustment provision pursuant to which upon completion of the IPO, and the conversion of the Series B preferred stock in connection therewith, the number of shares issuable upon exercise of the warrants was adjusted to be equal to 10% of the aggregate number of common stock shares issued by the Company upon conversion of 1,336,485 shares of Series A preferred stock (the “Preferred A Adjustment Provision”). The Second Amended and Restated Certificate of Incorporation that was approved on March 28, 2019 amended and fixed the conversion price of the Series A preferred stock at $1.40. As a result, on August 28, 2019, the Company elected to amend and reissue the Preferred A Placement Warrants, thereby reducing the exercise price to $1.40 and increasing the number of warrant shares by 109,200 to a total of 242,848 warrant shares. In connection with the IPO, pursuant to the Preferred A Adjustment Provision variable settlement provision, the number of shares of common stock subject to the Preferred A Placement Warrants settled, resulting in an additional 50,195 shares of common stock. Preferred A Lead Investor Warrants During February 2021, a total of 52,500 warrants for common stock were issued to advisors to the Company at a weighted average exercise price of $0.0125 per share. The resulting fair value of the warrants for common stock is not significant. Preferred B Placement Warrants On April 16, 2019, in connection with the Series B preferred stock offering, the Company issued warrants (“Preferred B Placement Warrants”) to purchase 414,270 shares of its common stock to NSC, Newbridge Securities Corporation, and five individuals at LPV. The Preferred B Placement Warrants have a term of five years and their exercise price is equal to $2.10, the conversion price of Series B preferred stock. The Preferred B Placement Warrants included an adjustment provision pursuant to which upon completion of the IPO, and the conversion of the Series B preferred stock in connection therewith, the number of shares issuable upon exercise of the warrants was adjusted to be equal to 10% of the aggregate number of common stock shares issued by the Company upon conversion of 4,142,270 shares of Series B preferred stock(the “Preferred B Adjustment Provision”). In connection with the IPO, pursuant to the Preferred B Adjustment Provision variable settlement provision, the number of shares of common stock subject to the Preferred B Placement Warrants settled, resulting in an additional 49,528 shares of common stock. Convertible Note Placement Warrants In connection with the Convertible Notes, the Company issued 10,000 and 204,500 warrants to purchase common stock, to a noteholder and its brokers, respectively. The warrants have a five-year life and are initially exercisable into common stock at $2.97 per share with the warrants ultimately being exercisable into common stock at the final Conversion Price of the Convertible Notes. When the Convertible Notes converted at the IPO date as described in Note 7, the exercise price of the warrants was adjusted to equal the Conversion Price, which is $2.57. During March 2021, 42,220 of these warrants to purchase common stock were cancelled. Underwriter Warrants In connection with the IPO, the Company issued the underwriter a warrant to purchase shares of common stock equal to 9.79% of the shares of common stock sold in the IPO or 956,973 shares. The warrant is exercisable at $6.00 per share and has a 5-year term. The warrant is subject to a six-month lock-up period. Additionally, the underwriter has contractually agreed that it will not sell, transfer, assign, pledge, or hypothecate this warrant or the securities underlying this warrant, nor will it engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of this warrant or the underlying securities for a period of 540 days (approximately 18 months) from the IPO. The following is a summary of the Company’s warrant activity for the three months ended March 31, 2021: Warrant Issuance Issuance Exercise Outstanding, Granted Exercised Canceled/ Variable Settlement Provision Adjustment Outstanding, Expiration Preferred A Placement Warrants March and April 2018 and August 2019 $ 1.40 242,847 — — — 50,195 293,042 March and April 2023 Preferred A Lead Investor Warrants February 2021 $ 0.0125 — 52,500 — — — 52,500 March 2023 Preferred B Placement Warrants April 2019 $ 2.10 414,270 — — — 49,528 463,798 April 2024 Convertible Notes Placement Warrants August 2020 $ 2.97 214,050 — — (42,220 ) — 171,830 August 2025 Underwriter warrants March 2021 $ 6.00 — 956,973 — — — 956,973 March 2026 871,167 1,009,473 — (42,220 ) 99,723 1,938,143 Warrants Classified as Liabilities Preferred A Placement Warrants and Preferred B Placement Warrants The Preferred A Placement Warrants and Preferred B Placement Warrants were initially classified as a derivative liability because their variable terms did not qualify these as being indexed to the Company’s own common stock and will be measured at fair value on a recurring basis. As a result of the conversion of the Preferred Stock into common stock in connection with the IPO, and the related impact of the Preferred A Adjustment Provision and the Preferred B Adjustment Provision, the number of warrant shares that are convertible is no longer variable. Accordingly, the Preferred A Placement Warrants and Preferred B Placement Warrants were determined to be indexed to the Company’s own common stock and will no longer be measured at fair value on a recurring basis. Instead the Preferred A Placement Warrants and the Preferred B Placement Warrants were determined to be equity instruments, and the liability was recorded at fair value with the change in fair value recorded in the condensed statement of operations and comprehensive loss and reclassified to additional paid-in capital at their estimated fair value at the IPO date. Convertible Notes Placement Warrants The Convertible Notes Placement Warrants are classified as a derivative liability because the exercise price was variable, thus these do not qualify as being indexed to the Company’s own common stock and will be measured at fair value on a recurring basis. As a result of the conversion of the Convertible Notes into common stock in connection with the IPO, the exercise price is no longer variable. Accordingly, the Convertible Notes Placement Warrants were determined to be indexed to the Company’s own common stock and will no longer be measured at fair value on a recurring basis. Instead the Convertible Notes Placement Warrants were determined to be equity instruments, and the liability was recorded at fair value with the change in fair value recorded in the condensed statement of operations and comprehensive loss and reclassified to additional paid-in capital at their estimated fair value at the IPO date. Estimated Fair Value of Outstanding Warrants Classified as Liabilities The estimated fair value of outstanding warrants classified as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the condensed statements of operations and comprehensive loss as a change in fair value of warrant liability. The changes in fair value of the outstanding warrants classified as liabilities for the three months ended March 31, 2021 were as follows (in thousands): Warrant Issuance Warrant liability, Fair value Fair value Change in fair Reclassified Warrant Preferred A Placement Warrants $ 518 $ — $ — $ 575 $ (1,093 ) $ — Preferred B Placement Warrants 708 — — 800 (1,508 ) $ — Convertible Notes Placement Warrants 323 — — 206 (529 ) $ — $ 1,549 $ — $ — $ 1,581 $ (3,130 ) $ — The changes in fair value of the warrant liability for the three months ended March 31, 2020 were as follows (in thousands): Warrant Issuance Warrant liability, Fair value Fair value Change in fair Warrant liability, Preferred A Placement Warrants $ 12 $ — $ — $ (8 ) $ 4 Preferred B Placement Warrants 20 — — (15 ) 5 $ 32 $ — $ — $ (23 ) $ 9 The fair values of the outstanding warrants accounted for as liabilities at the IPO date are calculated using the Black-Scholes option pricing model with the following assumptions: Black-Scholes Fair Value Assumptions at IPO Date Warrant Issuance Dividend Expected Risk-Free Expected Preferred A Placement Warrants – % 59.21 % 0.14 % 2.0 years Preferred B Placement Warrants – % 58.51 % 0.30 % 3.0 years Convertible Note Placement Warrants – % 52.28 % 0.82 % 4.4 years Upon the conversion of the redeemable convertible preferred stock and the Convertible Notes into common stock at the IPO date, the estimated fair value of the outstanding warrants accounted for as liabilities of $3.1 million was reclassified to additional paid-in capital. The fair values of the outstanding warrants accounted for as liabilities at December 31, 2020 are calculated using the Black-Scholes option pricing model with the following assumptions: Black-Scholes Fair Value Assumptions - December 31, 2020 Warrant Issuance Dividend Expected Risk-Free Expected Preferred A Placement Warrants – % 67.75 % 0.13 % 2.2 years Preferred B Placement Warrants – % 55.76 % 0.17 % 3.3 years Convertible Note Placement Warrants – % 52.93 % 0.36 % 4.7 years The fair values of the outstanding warrants accounted for as liabilities at March 31, 2020 are calculated using the Black-Scholes option pricing model with the following assumptions: Black-Scholes Fair Value Assumptions – March 31, 2020 Warrant Issuance Dividend Expected Risk-Free Expected Preferred A Placement Warrants – % 48.82 % 0.29 % 3.0 years Preferred B Placement Warrants – % 63.28 % 2.40 5.0 years Warrants Classified as Equity Certain warrants are classified as equity instruments since they do not meet the characteristics of a liability or a derivative and are recorded at fair value on the date of issuance using the Black-Scholes option pricing mod Black-Scholes Fair Value Assumptions Warrant Issuance Issuance Date Fair Dividend Expected Risk-Free Expected Underwriter Warrants March 2021 $ 2,349 – % 52.58 % 0.82 % 5.0 years

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	Note 10 – Stock-based Compensation 2019 Equity Incentive Plan Effective as of November 18, 2019, the Company adopted the 2019 Omnibus Incentive Plan (“2019 Plan”) administered by the Board. The 2019 Plan provides for the issuance of incentive stock options, non-statutory stock options, and restricted stock awards, for the purchase of up to a total of 4,000,000 shares of the Company’s common stock to employees, directors, and consultants and replaces the previous plan. The Board or a committee of the Board has the authority to determine the amount, type, and terms of each award. The options granted under the 2019 Plan generally have a contractual term of ten years and a vesting term of four years with a one-year cliff. The exercise price for options granted under the 2019 Plan must generally be at least equal to 100% of the fair value of the Company’s common stock at the date of grant, as determined by the Board. The incentive stock options granted under the 2019 Plan to 10% or greater stockholders must have an exercise price at least equal to 110% of the fair value of the Company’s common stock at the date of grant, as determined by the Board, and have a contractual term of ten years. On September 30, 2020, the Board approved an increase in the aggregate number of shares of common stock that may be issued pursuant to the 2019 Plan from 4,000,000 to 4,500,000. On December 7, 2020, the Board approved an increase in the aggregate number of shares of common stock that may be issued pursuant to the 2019 Plan from 4,500,000 to 6,000,000. In connection with the closing of the IPO, effective as of March 25, 2021 the 2019 Plan was amended and restated as a result of which the aggregate number of shares of common stock that may be issued pursuant to the 2019 Plan was increased from 6,000,000 to 7,400,000. As of March 31, 2021, the Company had 1,340,322 shares available for future grant under the 2019 Plan. Stock Options Stock option activity for the three months ended March 31, 2021 was as follows (in thousands, except share, per share, and remaining life data): Number of Weighted Average Exercise Price Weighted Average Remaining Life Intrinsic Outstanding at December 31, 2020 3,188,011 $ 0.66 9.0 years $ 8,155 Granted 1,415,000 $ 3.26 Exercised (134,541 ) $ 0.56 Cancelled (100,833 ) $ 0.47 Outstanding at March 31, 2021 4,367,637 $ 1.51 9.1 years $ 16,410 Exercisable as of March 31, 2021 1,590,688 $ 0.46 8.8 years $ 7,143 Vested and expected to vest as of March 31, 2021 4,317,437 $ 1.52 9.2 years $ 16,410 The weighted-average grant date fair value of options granted during the three months ended March 31, 2021 and 2020 was $2.66 and $0.21 per share, respectively. During the three months ended March 31, 2021 and 2020, 134,531 and no options were exercised for proceeds of $76,000 and $0, respectively. The fair value of the 187,763 and 152,899 options that vested during the three months ended March 31, 2021 and 2020 was approximately $0.1 million and $32,000, respectively. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of the stock options was estimated using the following weighted average assumptions for the three months ended March 31, 2021 and 2020. Three months ended March 31, 2021 2020 Dividend yield – % – % Expected volatility 67.70 % 61.93 % Risk-free interest rate 0.64 % 1.48 % Expected life 6.05 years 5.57 years Dividend Rate Expected Volatility Risk-Free Interest Rate Expected Term Forfeiture Rate The Company has recorded stock-based compensation expense for the three months ended March 31, 2021 and 2020 related to the issuance of stock option awards to employees and nonemployees in the statement of operations and comprehensive loss as follows: Three months ended March 31, 2021 2020 Research and development $ 79 $ 13 General and administrative 276 36 $ 355 $ 49 As of March 31, 2021, unamortized compensation expense related to unvested stock options was approximately $6.5 million, which is expected to be recognized over a weighted average period of 3.2 years.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	Note 11 – Commitments and Contingencies Operating Leases As of March 31, 2021, the Company had one office lease for facility space in Dublin, California. The lease expires in September 2021, and future minimum lease payments during 2021 are approximately $27,600. Rent expense for the three months ended March 31, 2021 and 2020 is insignificant. Litigation From time to time, the Company may become involved in various litigation and administrative proceedings relating to claims arising from its operations in the normal course of business. Management is not currently aware of any matters that may have a material adverse impact on the Company’s business, financial position, results of operations or cash flows. Indemnification The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual. No amounts associated with such indemnifications have been recorded as of March 31, 2021.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	Note 12 – NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS The following table sets for the computation of the basic and diluted net loss per share attributable to common stockholders during the three months ended March 31, 2021 and 2020 is as follows (in thousands, except share and per share data): Three Months Ended March 31, Three Months Ended March 31, 2021 2020 Numerator: Net loss and comprehensive loss $ (5,608 ) $ (2,025 ) Accretion and dividends on redeemable convertible preferred stock (2,489 ) (1,956 ) Net loss attributable to common stockholders $ (8,097 ) $ (3,981 ) Denominator: Weighted-average common shares outstanding 8,049,048 2,524,209 Net loss per share attributable to common stockholders, basic and diluted $ (1.01 ) $ (1.58 ) The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the three months ended March 31, 2021 and 2020 because including them would have been antidilutive are as follows: Three Months Ended March 31, Three Months Ended March 31, 2021 2020 Shares of redeemable convertible preferred stock — 10,849,933 Non-vested shares under restricted stock grants 841,667 1,851,667 Shares related to convertible promissory notes — 588,220 Shares subject to options to purchase common stock 4,317,437 3,062,478 Shares subject to warrants to purchase common stock 1,938,143 960,117 Total 7,097,247 17,312, 415 For the three months ended March 31, 2021 and 2020, performance based option awards for 50,200 shares of common stock are not included in in the table above or considered in the calculation of diluted earnings per share until the performance conditions of the option award are considered probable by the Company.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Note 13 – Subsequent Events On April 15, 2021, the Company executed a lease agreement for corporate office space. The lease will commence when the improvements are completed by the landlord and the Company has access to the facility. The lease term is 40 months, and the base rent is approximately $14,000 per month for the first twelve months, with subsequent escalation provisions for latter months. The Company paid a security deposit of approximately $47,000. The Company has granted common stock options t On April 28, 2021, the Company established Movano Ireland Limited, organized under the laws of Ireland, as a wholly owned subsidiary of the Company.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements include the accounts of the Company and have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. The unaudited and condensed financial statements have been prepared on the same basis as the annual financial statements. In the opinion of management, the accompanying unaudited and condensed financial statements reflect all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021. The condensed balance sheet as of December 31, 2020 has been derived from audited financial statements at that date but does not include all the information required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and notes thereto for the preceding fiscal year included in Amendment No. 2 to the Company’s Registration Statement on Form S-1 filed with the SEC on March 17, 2021.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock, stock options and warrants, the valuation of the embedded redemption derivative liability and income taxes. Estimates are periodically reviewed considering changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.
Segment Information	Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment. The Company’s chief operating decision maker is the chief executive officer.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.
Concentrations of Credit Risk and Off-Balance Sheet Risk	Concentrations of Credit Risk and Off-Balance Sheet Risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. All cash and cash equivalents are held in United States financial institutions. Cash equivalents consist of interest-bearing money market accounts. The amounts deposited in the money market accounts exceeds federally insured limits. The Company has not experienced any losses related to this account and believes the associated credit risk to be minimal due to the financial condition of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets were comprised of prepaid expenses, other current receivables, and deferred offering costs, which consist of legal, accounting, filing and other fees related to the IPO that were capitalized prior to the IPO. The deferred offering costs were offset against proceeds from the IPO upon the effectiveness of the IPO within additional paid-in capital. As of March 31, 2021 and December 31, 2020, offering costs of approximately $0 and $0.5 million were capitalized, respectively.
Paycheck Protection Program Loan	Paycheck Protection Program Loan The Company accounts for funds received from the Paycheck Protection Program as a financial liability with interest accrued and expensed over the term of the loan under the effective interest method. The loan will remain recorded as a liability until the Company has been legally released from the liability or the Company repays the liability. Any amount that is ultimately forgiven by the lender would be recognized in the statement of operations and comprehensive loss as a gain extinguishment.
Convertible Financial Instruments	Convertible Financial Instruments The Company bifurcates embedded redemption and conversion options from their host instruments and accounts for them as freestanding derivative financial instruments at fair value if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Debt discounts under these arrangements are amortized to interest expense using the interest method over the earlier of the term of the related debt or their earliest date of redemption. From time to time, the Company issues convertible financial instruments to nonemployees in payment for services that are provided. Until the services are completely rendered, the Company will expense the principal and any interest earned prior to the service completion to the representative expense account for the services performed and will record a noncurrent liability for the expected amount of the principal balance. Upon completion of the services, the Company will reclassify the noncurrent liability balance to the balance of an outstanding convertible financial instrument and assess the embedded redemption and conversion options that are applicable at that time.
Beneficial Conversion Feature	Beneficial Conversion Feature If the conversion feature of conventional convertible promissory notes provides for a rate of conversion that is below market value, this feature is characterized as a beneficial conversion feature (“BCF”). A BCF is recorded by the Company as a debt discount and as additional paid-in capital on the condensed balance sheet. In those circumstances, the convertible debt is recorded net of the discount related to the BCF and the Company amortizes the discount to interest expense over the life of the debt using the effective interest method.
Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock The Company records all shares of redeemable convertible preferred stock at their respective issuance price less issuance costs on the dates of issuance. Under certain circumstances the Company will be required to redeem the Series A and Series B redeemable convertible preferred stock unless an IPO has been consummated prior to April 1, 2021, or an extension or waiver is obtained upon approval of a majority of the holders of such preferred stock. As the preferred stock becomes redeemable due to the passage of time, the Company considers the preferred stock to be redeemable as of April 1, 2021. The Company records the accretion of the Series A and B preferred stock balances to their respective redemption amounts using the effective interest method. The redeemable convertible preferred stock is presented outside of stockholders’ deficit on the condensed balance sheet as of December 31, 2020. Upon the IPO, the redeemable convertible preferred stock converted in to 11,436,956 shares of common stock.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. As the Company maintained a full valuation allowance against its deferred tax assets, the changes resulted in no provision or benefit from income taxes during the three months ended March 31, 2021 and 2020. The Company accounts for unrecognized tax benefits using a more-likely-than-not threshold for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. The Company establishes a liability for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. The Company records an income tax liability, if any, for the difference between the benefit recognized and measured and the tax position taken or expected to be taken on the Company’s tax returns. To the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The liability is adjusted considering changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of liability provisions and changes to the liability that are considered appropriate. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur.
Stock-Based Compensation	Stock-Based Compensation The Company measures equity classified stock-based awards granted to employees, directors, and nonemployees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term, the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company accounts for forfeitures as they occur.
Early Exercised Stock Option Liability	Early Exercised Stock Option Liability Upon the early exercise of stock options by employees, the Company records as a liability the purchase price of unvested common stock that the Company has a right to repurchase if and when the employment of the stockholder terminates before the end of the requisite service period. The proceeds originally recorded as a liability are reclassified to additional paid-in capital as the Company’s repurchase right lapses.
Fair Value Measurements	Fair Value Measurements The Company accounts for certain of its financial assets and liabilities at fair value. The Company uses a three-level hierarchy, which prioritizes, within the measurement of fair value, the use of market-based information over entity-specific information for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date. Fair value focuses on an exit price and is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The inputs or methodology used for valuing financial instruments are not necessarily an indication of the risk associated with investing in those financial instruments. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Level 3 Significant unobservable inputs that cannot be corroborated by market data. The following tables provide a summary of the assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands). March 31, 2021 Fair Value Level 1 Level 2 Level 3 Assets – money market funds $ 46,328 $ 46,328 $ — $ — December 31, 2020 Fair Value Level 1 Level 2 Level 3 Assets – money market funds $ 5,181 $ 5,181 $ — $ — Warrant liability $ 1,549 $ — $ — $ 1,549 Derivative liability $ 121 $ — $ — $ 121 The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. At December 31, 2020, the warrants related to the Series A preferred stock issuance, the Series B preferred stock issuance, and the convertible promissory notes and the derivative liability related to the issuance of convertible promissory notes are classified within level 3 of the valuation hierarchy. The instruments are not present at March 31, 2021 in light of accounting ramifications of the IPO, which are discussed further in Note 6 and Note 9. The carrying amounts of cash and cash equivalents, prepaid expenses, payroll tax credit, accounts payable and accrued liabilities approximate fair value due to the short-term nature of these instruments. Based upon interest rates currently available to the Company for debt with similar terms, the carrying values of the Company’s convertible promissory notes and Paycheck Protection Program Loan are approximately equal to their fair values.
Net Loss per Share Attributable to Common Stockholders	Net Loss per Share Attributable to Common Stockholders Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. The net loss attributable to common stockholders is calculated by adjusting the net loss of the Company for the accretion on the Series A and B redeemable convertible preferred stock and cumulative dividends on Series A and B redeemable convertible preferred stock. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since the effects of potentially dilutive securities are antidilutive.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In December 2019, the FASB issued Accounting Standards Update 2019-12, Income Taxes (Topic 740 In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Schedule of the assets and liabilities that are measured at fair value on a recurring basis	March 31, 2021 Fair Value Level 1 Level 2 Level 3 Assets – money market funds $ 46,328 $ 46,328 $ — $ — December 31, 2020 Fair Value Level 1 Level 2 Level 3 Assets – money market funds $ 5,181 $ 5,181 $ — $ — Warrant liability $ 1,549 $ — $ — $ 1,549 Derivative liability $ 121 $ — $ — $ 121

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	March 31, December 31, 2021 2020 Office equipment and furniture $ 43 $ 43 Test equipment 33 22 Total property and equipment 76 65 Less: accumulated depreciation (28 ) (27 ) Total property and equipment, net $ 48 $ 38

Other Current Liabilities (Tabl

Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2021
Other Current Liabilities [Abstract]
Schedule of other current liabilities	March 31, December 31, 2021 2020 Accrued research and development $ — $ 197 Accrued compensation 380 184 Accrued vacation 218 192 Accrued legal expense 85 41 Accrued accounting and consulting expense 228 40 Other 63 12 $ 974 $ 666

Convertible Promissory Notes (T

Convertible Promissory Notes (Tables)	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Schedule of convertible note	Conversion Event Description Conversion Price Automatic Conversion – Next Qualified Equity Financing Upon the closing of a Next Qualified Equity Financing (defined as greater than $5,000,000), the Convertible Notes are converted into shares issued equal to the outstanding balance divided by the Conversion Price An amount equal to the lower of (i) 80% of the lowest per-share selling price of such stock sold by the Company at the Next Qualified Equity Financing or (ii) the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents (defined as fully diluted common shares for all outstanding securities, excluding common shares reserved for issuance or exercise of options or grants in the future) immediately prior to Next Financing Closing Automatic Conversion – Change of Control (defined as consolidation or merger of the Company or transfer of a majority of share ownership or disposition of substantially all assets of the Company) If at any time before payment or conversion of the balance, the Company effects a Change of Control, all of the balance outstanding immediately prior to such Change of Control will automatically convert into the most senior series of Preferred Stock outstanding immediately prior to such Change of Control at the Conversion Price. An amount equal to the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to such Change of Control. Automatic Conversion – Maturity Date If the Company has not paid or otherwise converted the entire balance before the Maturity Date, then on the Maturity Date, all of the balance then outstanding will automatically convert into the most senior series of Preferred Stock outstanding as of the Maturity Date at the Conversion Price then in effect. An amount equal to the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents as of the Maturity Date. Automatic Conversion – IPO If at any time before payment or conversion of the balance, the Company consummates an IPO, all of the balance outstanding immediately prior to the IPO will automatically convert into Common Stock at the Conversion Price. An amount equal to the lower of (i) 80% of the lowest per-share selling price of the common stock sold by the Company in an IPO or (ii) the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to closing of an IPO. Conversion Event Description Conversion Price Optional Conversion If at any time while the Convertible Notes are still outstanding the Company sells stock in a single transaction or in a series of related transactions that does not constitute a Next Qualified Equity Financing (and thus is defined as a Non-qualified Financing), then, at the closing of the Nonqualified Financing, the balance then outstanding may be converted, at the option of the holder, into that number of shares of Non-qualified Preferred Stock (preferred stock sold in the Non-qualified Financing) determined by dividing (i) the balance by (ii) the Conversion Price then in effect. An amount equal to the lowest per share selling price of Nonqualified Preferred Stock sold by the Company for new cash investment in the Non-Qualified Financing.
Schedule of fair value of the embedded redemption derivative liability	Financing Date Maturity Date Probability of Conversion at Financing 80% 20% Expected Term March 2021 February 2022 Conversion Ratio 1.25 N/A Discount Rate 1.68% to 11.67% N/A Financing Date Maturity Date Probability of Conversion at Financing 80% 20% Expected Term March 2021 February 2022 Conversion Ratio 1.25 N/A Discount Rate 6.18% to 11.67% N/A
Schedule of fair value of the derivative liability	Warrant Issuance December 31, Fair Value at Change in March 31, Derivative liability $ 121 — (121 ) $ — Warrant Issuance December 31, Fair Value at Change in March 31, Derivative liability $ — 71 32 $ 103

Common Stock (Tables)

Common Stock (Tables)	3 Months Ended
	Mar. 31, 2021
Stockholders' Equity Note [Abstract]
Schedule of common stock reserved for future issuance	Warrants to purchase common stock 1,938,143 Stock options outstanding 4,367,637 Stock options available for future grants 1,340,322 Total 7,646,102

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	3 Months Ended
	Mar. 31, 2021
Disclosure Text Block Supplement [Abstract]
Schedule of company's warrant activity	Warrant Issuance Issuance Exercise Outstanding, Granted Exercised Canceled/ Variable Settlement Provision Adjustment Outstanding, Expiration Preferred A Placement Warrants March and April 2018 and August 2019 $ 1.40 242,847 — — — 50,195 293,042 March and April 2023 Preferred A Lead Investor Warrants February 2021 $ 0.0125 — 52,500 — — — 52,500 March 2023 Preferred B Placement Warrants April 2019 $ 2.10 414,270 — — — 49,528 463,798 April 2024 Convertible Notes Placement Warrants August 2020 $ 2.97 214,050 — — (42,220 ) — 171,830 August 2025 Underwriter warrants March 2021 $ 6.00 — 956,973 — — — 956,973 March 2026 871,167 1,009,473 — (42,220 ) 99,723 1,938,143
Schedule of changes in fair value of the warrant liability	Warrant Issuance Warrant liability, Fair value Fair value Change in fair Reclassified Warrant Preferred A Placement Warrants $ 518 $ — $ — $ 575 $ (1,093 ) $ — Preferred B Placement Warrants 708 — — 800 (1,508 ) $ — Convertible Notes Placement Warrants 323 — — 206 (529 ) $ — $ 1,549 $ — $ — $ 1,581 $ (3,130 ) $ — Warrant Issuance Warrant liability, Fair value Fair value Change in fair Warrant liability, Preferred A Placement Warrants $ 12 $ — $ — $ (8 ) $ 4 Preferred B Placement Warrants 20 — — (15 ) 5 $ 32 $ — $ — $ (23 ) $ 9
Schedule of Black-Scholes option pricing model assumptions	Black-Scholes Fair Value Assumptions at IPO Date Warrant Issuance Dividend Expected Risk-Free Expected Preferred A Placement Warrants – % 59.21 % 0.14 % 2.0 years Preferred B Placement Warrants – % 58.51 % 0.30 % 3.0 years Convertible Note Placement Warrants – % 52.28 % 0.82 % 4.4 years
Schedule of Black-Scholes option pricing model assumptions	Black-Scholes Fair Value Assumptions - December 31, 2020 Warrant Issuance Dividend Expected Risk-Free Expected Preferred A Placement Warrants – % 67.75 % 0.13 % 2.2 years Preferred B Placement Warrants – % 55.76 % 0.17 % 3.3 years Convertible Note Placement Warrants – % 52.93 % 0.36 % 4.7 years Black-Scholes Fair Value Assumptions – March 31, 2020 Warrant Issuance Dividend Expected Risk-Free Expected Preferred A Placement Warrants – % 48.82 % 0.29 % 3.0 years Preferred B Placement Warrants – % 63.28 % 2.40 5.0 years
Schedule of fair value at issuance for warrants	Black-Scholes Fair Value Assumptions Warrant Issuance Issuance Date Fair Dividend Expected Risk-Free Expected Underwriter Warrants March 2021 $ 2,349 – % 52.58 % 0.82 % 5.0 years

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of stock option activity	Number of Weighted Average Exercise Price Weighted Average Remaining Life Intrinsic Outstanding at December 31, 2020 3,188,011 $ 0.66 9.0 years $ 8,155 Granted 1,415,000 $ 3.26 Exercised (134,541 ) $ 0.56 Cancelled (100,833 ) $ 0.47 Outstanding at March 31, 2021 4,367,637 $ 1.51 9.1 years $ 16,410 Exercisable as of March 31, 2021 1,590,688 $ 0.46 8.8 years $ 7,143 Vested and expected to vest as of March 31, 2021 4,317,437 $ 1.52 9.2 years $ 16,410
Schedule of weighted average assumptions for fair value of options estimated	Three months ended March 31, 2021 2020 Dividend yield – % – % Expected volatility 67.70 % 61.93 % Risk-free interest rate 0.64 % 1.48 % Expected life 6.05 years 5.57 years
Schedule of stock-based compensation expense to employees and non-employees	Three months ended March 31, 2021 2020 Research and development $ 79 $ 13 General and administrative 276 36 $ 355 $ 49

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Schedule of basic and diluted net loss per share attributable to common stockholders	Three Months Ended March 31, Three Months Ended March 31, 2021 2020 Numerator: Net loss and comprehensive loss $ (5,608 ) $ (2,025 ) Accretion and dividends on redeemable convertible preferred stock (2,489 ) (1,956 ) Net loss attributable to common stockholders $ (8,097 ) $ (3,981 ) Denominator: Weighted-average common shares outstanding 8,049,048 2,524,209 Net loss per share attributable to common stockholders, basic and diluted $ (1.01 ) $ (1.58 )
Schedule of diluted net loss per share attributable to common stockholders	Three Months Ended March 31, Three Months Ended March 31, 2021 2020 Shares of redeemable convertible preferred stock — 10,849,933 Non-vested shares under restricted stock grants 841,667 1,851,667 Shares related to convertible promissory notes — 588,220 Shares subject to options to purchase common stock 4,317,437 3,062,478 Shares subject to warrants to purchase common stock 1,938,143 960,117 Total 7,097,247 17,312, 415

Business Organization, Nature_2

Business Organization, Nature of Operations (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2021	Aug. 31, 2019	Dec. 31, 2018
Business Organization, Nature of Operations (Details) [Line Items]
Convertible promissory of net proceeds	$ 11.1
Paycheck Protection Program loans	0.4
Price per share (in Dollars per share)		$ 2.10	$ 0.0125
Net proceeds	44.3
Underwriting discounts	3.3
Offering expenses	$ 1.3
Ownership percentage	10.00%
Common Stock [Member] | Initial Public Offering [Member]
Business Organization, Nature of Operations (Details) [Line Items]
Shares issued (in Shares)	9,775,000
Price per share (in Dollars per share)	$ 5

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Offering costs	$ 0	$ 0.5
Redeemable convertible preferred stock share (in Shares)	11,436,956

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of the assets and liabilities that are measured at fair value on a recurring basis - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Summary of Significant Accounting Policies (Details) - Schedule of the assets and liabilities that are measured at fair value on a recurring basis [Line Items]
Assets – money market funds	$ 46,328	$ 5,181
Warrant liability		1,549
Derivative liability		121
Fair Value, Inputs, Level 1 [Member]
Summary of Significant Accounting Policies (Details) - Schedule of the assets and liabilities that are measured at fair value on a recurring basis [Line Items]
Assets – money market funds	46,328	5,181
Warrant liability
Derivative liability
Fair Value, Inputs, Level 2 [Member]
Summary of Significant Accounting Policies (Details) - Schedule of the assets and liabilities that are measured at fair value on a recurring basis [Line Items]
Assets – money market funds
Warrant liability
Derivative liability
Fair Value, Inputs, Level 3 [Member]
Summary of Significant Accounting Policies (Details) - Schedule of the assets and liabilities that are measured at fair value on a recurring basis [Line Items]
Assets – money market funds
Warrant liability		1,549
Derivative liability		$ 121

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 1,000	$ 3,000

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of Property and Equipment - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Schedule of Property and Equipment [Abstract]
Office equipment and furniture	$ 43	$ 43
Test equipment	33	22
Total property and equipment	76	65
Less: accumulated depreciation	(28)	(27)
Total property and equipment, net	$ 48	$ 38

Other Current Liabilities (Deta

Other Current Liabilities (Details) - Schedule of other current liabilities - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Schedule of other current liabilities [Abstract]
Accrued research and development		$ 197
Accrued compensation	380	184
Accrued vacation	218	192
Accrued legal expense	85	41
Accrued accounting and consulting expense	228	40
Other	63	12
Total other current liabilities	$ 974	$ 666

Paycheck Protection Program L_2

Paycheck Protection Program Loan (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	May 27, 2020	Apr. 23, 2020
Paycheck Protection Program Loan (Details) [Line Items]
Unsecured loan		$ 351,000	$ 351,000
Interest rate			1.00%
Minimum [Member]
Paycheck Protection Program Loan (Details) [Line Items]
Future payments	$323,000
Maximum [Member]
Paycheck Protection Program Loan (Details) [Line Items]
Future payments	$28,000

Convertible Promissory Notes (D

Convertible Promissory Notes (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Convertible Promissory Notes (Details) [Line Items]
Total proceeds	$ 11,800,000
Convertible Notes accrue interest	4.00%
Convertible Notes	$ 747,000		$ 247,000
Amount of future services			$ 500,000
Debt value			$747,000
Other noncurrent liabilities	23,000		$ 161,000
Additional non-employee services	50,000
Prepaid assets and other current expenses	1,919,000		691,000
Beneficial conversion feature	$ 0.5
Conversion price (in Dollars per share)	$ 2.5736
Warrants to purchase common stock were cancelled (in Shares)	42,220
Issuance costs	$ 83,000
Commissions	$ 612,000
Convertible note conversion, description	(i) 80% of the lowest per-share selling price of the stock sold by the Company in the Next Qualified Equity Financing or (ii) 80% of the lowest per-share selling price of the Conversion Stock sold by the Company in an IPO are deemed a redemption feature. The Company also concluded that those redemption features require bifurcation from the Convertible Notes and subsequent accounting in the same manner as a freestanding derivative.
Lowest price per share selling price percentage	80.00%
Interest expense	$ 800,000	$ 0
Debt Instrument, Unamortized Discount	0.4
Change in fair value of derivative liability	0.1
Convertible Notes Payable [Member]
Convertible Promissory Notes (Details) [Line Items]
Other noncurrent liabilities			150,000
Convertible notes for non-employee services	500,000
Prepaid assets and other current expenses	$ 300,000
Beneficial conversion feature			$ 500,000
Shares issued (in Shares)			10,000
Warrants (in Shares)			204,500
Conversion price (in Dollars per share)	$ 2,970
Common stock equivalents	$ 60,000,000
Outstanding principal	12,500,000
Interest due	400,000
Common stock equivalents	$ 12,900,000
Converted shares (in Shares)	5,015,494

Convertible Promissory Notes _2

Convertible Promissory Notes (Details) - Schedule of convertible note	3 Months Ended
	Mar. 31, 2021
Next Qualified Equity Financing [Member]
Convertible Promissory Notes (Details) - Schedule of convertible note [Line Items]
Description	Upon the closing of a Next Qualified Equity Financing (defined as greater than $5,000,000), the Convertible Notes are converted into shares issued equal to the outstanding balance divided by the Conversion Price
Conversion Price	An amount equal to the lower of (i) 80% of the lowest per-share selling price of such stock sold by the Company at the Next Qualified Equity Financing or (ii) the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents (defined as fully diluted common shares for all outstanding securities, excluding common shares reserved for issuance or exercise of options or grants in the future) immediately prior to Next Financing Closing
Change of Control [Member]
Convertible Promissory Notes (Details) - Schedule of convertible note [Line Items]
Description	If at any time before payment or conversion of the balance, the Company effects a Change of Control, all of the balance outstanding immediately prior to such Change of Control will automatically convert into the most senior series of Preferred Stock outstanding immediately prior to such Change of Control at the Conversion Price.
Conversion Price	An amount equal to the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to such Change of Control.
Maturity Date [Member]
Convertible Promissory Notes (Details) - Schedule of convertible note [Line Items]
Description	If the Company has not paid or otherwise converted the entire balance before the Maturity Date, then on the Maturity Date, all of the balance then outstanding will automatically convert into the most senior series of Preferred Stock outstanding as of the Maturity Date at the Conversion Price then in effect.
Conversion Price	An amount equal to the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents as of the Maturity Date.
Automatic Conversion Initial Public Offering [Member]
Convertible Promissory Notes (Details) - Schedule of convertible note [Line Items]
Description	If at any time before payment or conversion of the balance, the Company consummates an IPO, all of the balance outstanding immediately prior to the IPO will automatically convert into Common Stock at the Conversion Price.
Conversion Price	An amount equal to the lower of (i) 80% of the lowest per-share selling price of the common stock sold by the Company in an IPO or (ii) the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to closing of an IPO.
Option Conversion [Member]
Convertible Promissory Notes (Details) - Schedule of convertible note [Line Items]
Description	If at any time while the Convertible Notes are still outstanding the Company sells stock in a single transaction or in a series of related transactions that does not constitute a Next Qualified Equity Financing (and thus is defined as a Non-qualified Financing), then, at the closing of the Nonqualified Financing, the balance then outstanding may be converted, at the option of the holder, into that number of shares of Non-qualified Preferred Stock (preferred stock sold in the Non-qualified Financing) determined by dividing (i) the balance by (ii) the Conversion Price then in effect.
Conversion Price	An amount equal to the lowest per share selling price of Nonqualified Preferred Stock sold by the Company for new cash investment in the Non-Qualified Financing.

Convertible Promissory Notes _3

Convertible Promissory Notes (Details) - Schedule of fair value of the embedded redemption derivative liability	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Convertible Promissory Notes (Details) - Schedule of fair value of the embedded redemption derivative liability [Line Items]
Probability of Conversion at Financing	20.00%	20.00%
Expected Term	February 2022	February 2022
Conversion Ratio
Discount Rate
Financing Date [Member]
Convertible Promissory Notes (Details) - Schedule of fair value of the embedded redemption derivative liability [Line Items]
Probability of Conversion at Financing	80.00%	80.00%
Expected Term	2021	2021
Conversion Ratio	1 year 3 months	1 year 3 months
Financing Date [Member] | Minimum [Member]
Convertible Promissory Notes (Details) - Schedule of fair value of the embedded redemption derivative liability [Line Items]
Discount Rate	6.18%	1.68%
Financing Date [Member] | Maximum [Member]
Convertible Promissory Notes (Details) - Schedule of fair value of the embedded redemption derivative liability [Line Items]
Discount Rate	11.67%	11.67%

Convertible Promissory Notes _4

Convertible Promissory Notes (Details) - Schedule of fair value of the derivative liability - Warrant Issuance [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Servicing Liabilities at Fair Value [Line Items]
Derivative liability, beginning balance	$ 121
Fair Value at issuance date		71
Change in fair value	(121)	32
Derivative liability, ending balance		$ 103

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended		3 Months Ended	6 Months Ended
	Mar. 24, 2021	Mar. 28, 2019	Mar. 31, 2021	Aug. 31, 2019	Dec. 31, 2018
Redeemable Convertible Preferred Stock (Details) [Line Items]
Convertible preferred stock, description		(i) increased the number of shares of common stock the Company is authorized to issue to 22,069,652; (ii) increased the number of shares of preferred stock the Company was authorized to issue to 7,930,348, of which 2,692,253 shares were designated as Series A preferred stock and 5,238,095 shares were designated as Series B preferred stock; (iii) amended and set a fixed conversion price of Series A preferred stock to $1.40; and (iv) extended the IPO Commitment Date from April 1, 2020 to no later than March 31, 2021.
Original issue price per share (in Dollars per share)				$ 2.10	$ 0.0125
Convertible common stock (in Shares)			11,436,956
Preferred stock, description	(i) eliminated the Company’s Series A and Series B preferred stock, (ii) increased the authorized number of shares of common stock to 75,000,000 and (iii) authorized 5,000,000 shares of preferred stock at par value of $0.0001 per share. The significant rights and preferences of the preferred stock will be established by the Company’s Board of Directors (the “Board”) upon issuance of any such series of preferred stock in the future.
Redeemable convertible preferred stock outstanding (in Shares)			0
Series B Preferred Stock [Member]
Redeemable Convertible Preferred Stock (Details) [Line Items]
Stock issued during period (in Shares)				4,942,319
Stock price (in Dollars per share)				$ 2,100
Net cash proveeds				$ 9.3
Transaction price net of issuance costs				$ 9.3
Accumulated accretion			$ 11.5
Preferred stock carrying value			20.8
Series A Preferred Stock [Member]
Redeemable Convertible Preferred Stock (Details) [Line Items]
Accumulated accretion			8.2
Preferred stock carrying value			$ 14.5

Common Stock (Details)

Common Stock (Details) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Mar. 25, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2018	Aug. 31, 2019
Common Stock (Details) [Line Items]
Common stock shares authorized		75,000,000	22,069,652
Common stock , par value (in Dollars per share)		$ 0.0001	$ 0.0001
Common stock, shares issued		32,772,060	6,393,069
Shares of common stock for non-employee			17,000
Value of common stock issued for non-employee services (in Dollars)			$ 85,000
Original purchase price (in Dollars per share)				$ 0.0125	$ 2.10
Subject to the Repurchase Option		758,334	985,834
Stock Issued During Period Shares Stock Option Exercised		50,000
Repurchase liability (in Dollars)		$ 406,000	$ 417,000
Shares remain unvested		826,127	856,814
Weighted average vesting period		3 years
Restricted Stock [Member]
Common Stock (Details) [Line Items]
Shares of common stock for non-employee				3,640,000
Original purchase price (in Dollars per share)		$ 0.0125
IPO [Member]
Common Stock (Details) [Line Items]
Common stock shares authorized	75,000,000
Common stock , par value (in Dollars per share)	$ 0.0001
Aggregate amount converted (in Dollars)	$ 12,900,000
Converted into shares	5,015,494
Founder [Member]
Common Stock (Details) [Line Items]
Shares of common stock for non-employee				400,000
Original purchase price (in Dollars per share)		$ 12.5	$ 0.0125
Subject to the Repurchase Option		83,333	108,333
Series A Redeemable Convertible Preferred Stock [Member]
Common Stock (Details) [Line Items]
Converted into shares of common stock	11,436,956
Series B Redeemable Convertible Preferred Stock [Member]
Common Stock (Details) [Line Items]
Converted into shares of common stock	11,436,956

Common Stock (Details) - Schedu

Common Stock (Details) - Schedule of common stock reserved for future issuance - shares	Mar. 31, 2021	Dec. 31, 2020
Schedule of common stock reserved for future issuance [Abstract]
Warrants to purchase common stock	1,938,143
Stock options outstanding	4,367,637	3,188,011
Stock options available for future grants	1,340,322
Total	7,646,102

Common Stock Warrants (Details)

Common Stock Warrants (Details) - USD ($)	Mar. 14, 2018	Feb. 28, 2021	Apr. 16, 2019	Mar. 28, 2019	Mar. 31, 2021	Aug. 31, 2019	Aug. 28, 2019	Apr. 23, 2018
Common Stock Warrants (Details) [Line Items]
Warrants to purchase shares								133,648
Common stock shares issued percentage					10.00%
Conversion price (in Dollars per share)					$ 2.5736
Warrants for common stock issued		52,500
Weighted average exercise price (in Dollars per share)		$ 0.0125
Fair value of warrants liabilities (in Dollars)					$ 3.1
Preferred A Placement Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Shares issued	133,648
Term of warrants					5 years
Preferred A Placement Warrants 1 [Member]
Common Stock Warrants (Details) [Line Items]
Warrants to purchase shares							242,848
Exercise price per share (in Dollars per share)							$ 1.40
Increasing number of warrants							109,200
Preferred B Placement Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Shares issued			414,270
Term of warrants			5 years
Preferred B Lead Investor Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Shares issued				49,528
Convertible Notes Placement Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Shares issued					10,000
Term of warrants					5 years
Initial exercise price (in Dollars per share)					$ 2.97
Common stock cancelled (in Dollars)					$ 42,220
Underwriter warrants [Member]
Common Stock Warrants (Details) [Line Items]
Warrants to purchase shares					0.0979
Term of warrants					5 years
Exercise price per share (in Dollars per share)					$ 6
Sale of Stock, Price Per Share (in Dollars per share)					$ 956,973
Common Stock [Member] | Preferred B Placement Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Exercise price per share (in Dollars per share)			$ 0.10
Common stock shares conversion			4,142,270
Common Stock [Member] | Convertible Notes Placement Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Shares issued					204,500
Warrants Liabilities [Member] | Convertible Notes Placement Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Exercise price per share (in Dollars per share)					$ 2.57
Series A Preferred Stock [Member]
Common Stock Warrants (Details) [Line Items]
Common stock shares issued upon conversion shares					1,336,485
Conversion price (in Dollars per share)				$ 1.40
Series B Preferred Stock [Member]
Common Stock Warrants (Details) [Line Items]
Exercise price per share (in Dollars per share)			$ 2.10
Sale of Stock, Price Per Share (in Dollars per share)						$ 2,100

Common Stock Warrants (Detail_2

Common Stock Warrants (Details) - Schedule of company's warrant activity	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Class of Warrant or Right [Line Items]
Warrant Issuance, Outstanding begining	871,167
Warrant Issuance, Granted	1,009,473
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired	(42,220)
Warrant Issuance, Variable Settlement Provision Adjustment	99,723
Warrant Issuance, Outstanding ending	1,938,143
Preferred A Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Date	March and April 2018 and August 2019
Warrant Issuance, Excercise Price (in Dollars per share) | $ / shares	$ 1.40
Warrant Issuance, Outstanding begining	242,847
Warrant Issuance, Granted
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment	50,195
Warrant Issuance, Outstanding ending	293,042
Warrant Issuance, Expiration	March and April 2023
Preferred A Lead Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Date	February 2021
Warrant Issuance, Excercise Price (in Dollars per share) | $ / shares	$ 0.0125
Warrant Issuance, Outstanding begining
Warrant Issuance, Granted	52,500
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending	52,500
Warrant Issuance, Expiration	March 2023
Preferred B Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Date	April 2019
Warrant Issuance, Excercise Price (in Dollars per share) | $ / shares	$ 2.10
Warrant Issuance, Outstanding begining	414,270
Warrant Issuance, Granted
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment	49,528
Warrant Issuance, Outstanding ending	463,798
Warrant Issuance, Expiration	April 2024
Convertible Notes Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Date	August 2020
Warrant Issuance, Excercise Price (in Dollars per share) | $ / shares	$ 2.97
Warrant Issuance, Outstanding begining	214,050
Warrant Issuance, Granted
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired	(42,220)
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending	171,830
Warrant Issuance, Expiration	August 2025
Underwriter warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Date	March 2021
Warrant Issuance, Excercise Price (in Dollars per share) | $ / shares	$ 6
Warrant Issuance, Outstanding begining
Warrant Issuance, Granted	956,973
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending	956,973
Warrant Issuance, Expiration	March 2026

Common Stock Warrants (Detail_3

Common Stock Warrants (Details) - Schedule of changes in fair value of the warrant liability - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Common Stock Warrants (Details) - Schedule of changes in fair value of the warrant liability [Line Items]
Warrant Issuance, Warrant liability begining	$ 1,549	$ 32
Warrant Issuance, Fair value of warrants granted
Warrant Issuance, Fair value of warrants exercised
Warrant Issuance, Change in fair value of warrants	1,581	(23)
Warrant Issuance, Reclassified to additional paid-in capital	(3,130)
Warrant Issuance, Warrant liability ending		9
Preferred A Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule of changes in fair value of the warrant liability [Line Items]
Warrant Issuance, Warrant liability begining	518	12
Warrant Issuance, Fair value of warrants granted
Warrant Issuance, Fair value of warrants exercised
Warrant Issuance, Change in fair value of warrants	575	(8)
Warrant Issuance, Reclassified to additional paid-in capital	(1,093)
Warrant Issuance, Warrant liability ending		4
Preferred B Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule of changes in fair value of the warrant liability [Line Items]
Warrant Issuance, Warrant liability begining	708	20
Warrant Issuance, Fair value of warrants granted
Warrant Issuance, Fair value of warrants exercised
Warrant Issuance, Change in fair value of warrants	800	(15)
Warrant Issuance, Reclassified to additional paid-in capital	(1,508)
Warrant Issuance, Warrant liability ending		$ 5
Convertible Notes Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule of changes in fair value of the warrant liability [Line Items]
Warrant Issuance, Warrant liability begining	323
Warrant Issuance, Fair value of warrants granted
Warrant Issuance, Fair value of warrants exercised
Warrant Issuance, Change in fair value of warrants	206
Warrant Issuance, Reclassified to additional paid-in capital	(529)
Warrant Issuance, Warrant liability ending

Common Stock Warrants (Detail_4

Common Stock Warrants (Details) - Schedule option pricing model with the following assumptions	3 Months Ended
	Mar. 31, 2021
Preferred A Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule option pricing model with the following assumptions [Line Items]
Dividend Yield
Expected Volatility	59.21%
Risk-Free Interest Rate	0.14%
Expected Life	2 years
Preferred B Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule option pricing model with the following assumptions [Line Items]
Dividend Yield
Expected Volatility	58.51%
Risk-Free Interest Rate	0.30%
Expected Life	3 years
Convertible Note Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule option pricing model with the following assumptions [Line Items]
Dividend Yield
Expected Volatility	52.28%
Risk-Free Interest Rate	0.82%
Expected Life	4 years 146 days

Common Stock Warrants (Detail_5

Common Stock Warrants (Details) - Schedule of Black-Scholes option pricing model assumptions	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2020
Preferred A Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule of Black-Scholes option pricing model assumptions [Line Items]
Warrant Issuance, Dividend Yield
Warrant Issuance, Expected Volatility	48.82%	67.75%
Warrant Issuance, Risk-Free Interest Rate	0.29%	0.13%
Warrant Issuance, Expected Life	3 years	2 years 73 days
Preferred B Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule of Black-Scholes option pricing model assumptions [Line Items]
Warrant Issuance, Dividend Yield
Warrant Issuance, Expected Volatility	63.28%	55.76%
Warrant Issuance, Risk-Free Interest Rate	2.40%	0.17%
Warrant Issuance, Expected Life	5 years	3 years 109 days
Convertible Notes Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule of Black-Scholes option pricing model assumptions [Line Items]
Warrant Issuance, Dividend Yield
Warrant Issuance, Expected Volatility		52.93%
Warrant Issuance, Risk-Free Interest Rate		0.36%
Warrant Issuance, Expected Life		4 years 255 days

Common Stock Warrants (Detail_6

Common Stock Warrants (Details) - Schedule of fair value at issuance for warrants - Black-Scholes Fair Value Assumptions [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Common Stock Warrants (Details) - Schedule of fair value at issuance for warrants [Line Items]
Issuance Date	March 2021
Fair Value (in Dollars)	$ 2,349
Dividend Yield
Expected Volatility	52.58%
Risk-Free Interest Rate	0.82%
Expected Life	5 years

Stock-based Compensation (Detai

Stock-based Compensation (Details) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Nov. 18, 2019	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Mar. 25, 2021	Dec. 07, 2020	Sep. 30, 2020
Stock-based Compensation (Details) [Line Items]
Contractual term
Common stock, shares issued		32,772,060		6,393,069
Shares granted		1,340,322
Fair value (in Dollars per share)		$ 2.66
Grant date fair value of options granted (in Dollars per share)			$ 0.21
Number of options		7,646,102
Proceeds from stock options exercised (in Dollars)		$ 76,000	$ 0
Number of options		4,317,437
Unamortized compensation expense (in Dollars)		$ 355,000	$ 49,000
Weighted average period		3 years 73 days
Stock option [Member]
Stock-based Compensation (Details) [Line Items]
Unamortized compensation expense (in Dollars)		$ 6,500,000
Share-based Payment Arrangement, Option [Member]
Stock-based Compensation (Details) [Line Items]
Expected weighted average period				10 years
Contractual term		6 years 18 days	5 years 208 days
Fair value of options vested (in Dollars)		$ 187,763	$ 152,899
Number of options		0.1
Fair value of options vested (in Dollars per share)			$ 32,000
IPO [Member] | Minimum [Member]
Stock-based Compensation (Details) [Line Items]
Aggregate shares issued					6,000,000
IPO [Member] | Maximum [Member]
Stock-based Compensation (Details) [Line Items]
Aggregate shares issued					7,400,000
2019 Omnibus Incentive Plan [Member]
Stock-based Compensation (Details) [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	4,000,000
Fair value percentage	110.00%
Exercise price percentage	10.00%
Contractual term	10 years
Common stock, shares issued							4,500,000
Shares granted		1,340,322
Number of options		134,531
2019 Omnibus Incentive Plan [Member] | Minimum [Member]
Stock-based Compensation (Details) [Line Items]
Fair value percentage	100.00%
Common stock, shares issued						4,500,000	6,000,000
2019 Omnibus Incentive Plan [Member] | Maximum [Member]
Stock-based Compensation (Details) [Line Items]
Common stock, shares issued						4,000,000

Stock-based Compensation (Det_2

Stock-based Compensation (Details) - Schedule of stock option activity	3 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares
Schedule of stock option activity [Abstract]
Number of Options, Outstanding | shares	3,188,011
Weighted Average Exercise Price, Outstanding | $ / shares	$ 0.66
Weighted Average Remaining Life, Outstanding	9 years
Intrinsic Value, Outstanding | $	$ 8,155
Number of Options, Outstanding | shares	4,367,637
Weighted Average Exercise Price, Outstanding | $ / shares	$ 1.51
Weighted Average Remaining Life, Outstanding	9 years 36 days
Intrinsic Value, Outstanding | $	$ 16,410
Number of Options, Exercisable | shares	1,590,688
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.46
Weighted Average Remaining Life, Exercisable	8 years 292 days
Intrinsic Value, Exercisable | $	$ 7,143
Number of Options, Vested and expected to vest | shares	4,317,437
Weighted Average Exercise Price, Vested and expected to vest | $ / shares	$ 1.52
Weighted Average Remaining Life, Vested and expected to vest	9 years 73 days
Intrinsic Value, Vested and expected to vest | $	$ 16,410
Number of Options, Granted | shares	1,415,000
Weighted Average Exercise Price, Granted | $ / shares	$ 3.26
Weighted Average Remaining Life, Granted
Intrinsic Value, Granted | $
Number of Options, Exercised | shares	(134,541)
Weighted Average Exercise Price, Exercised | $ / shares	$ 0.56
Weighted Average Remaining Life, Exercised
Intrinsic Value, Exercised | $
Number of Options, Cancelled | shares	(100,833)
Weighted Average Exercise Price, Cancelled | $ / shares	$ 0.47
Weighted Average Remaining Life, Cancelled
Intrinsic Value, Cancelled | $

Stock-based Compensation (Det_3

Stock-based Compensation (Details) - Schedule of weighted average assumptions for fair value of options estimated - Options	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Stock-based Compensation (Details) - Schedule of weighted average assumptions for fair value of options estimated [Line Items]
Dividend yield
Expected volatility	67.70%	61.93%
Risk-free interest rate	0.64%	1.48%
Expected life	6 years 18 days	5 years 208 days

Stock-based Compensation (Det_4

Stock-based Compensation (Details) - Schedule of stock-based compensation expense to employees and non-employees - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 355	$ 49
Research and development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	79	13
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 276	$ 36

Commitments and Contingencies (

Commitments and Contingencies (Details)	Mar. 31, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
Future minimum lease payments	$ 27,600

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share [Abstract]
Performance based option awards	50,200	50,200

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of basic and diluted net loss per share attributable to common stockholders - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Numerator:
Net loss and comprehensive loss	$ (5,608)	$ (2,025)
Accretion and dividends on redeemable convertible preferred stock	(2,489)	(1,956)
Net loss attributable to common stockholders	$ (8,097)	$ (3,981)
Denominator:
Weighted-average common shares outstanding (in Shares)	8,049,048	2,524,209
Net loss per share attributable to common stockholders, basic and diluted (in Dollars per share)	$ (1.01)	$ (1.58)

Net Loss Per Share Attributab_5

Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of diluted net loss per share attributable to common stockholders - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Schedule of diluted net loss per share attributable to common stockholders [Abstract]
Shares of redeemable convertible preferred stock		10,849,933
Non-vested shares under restricted stock grants	841,667	1,851,667
Shares related to convertible promissory notes		588,220
Shares subject to options to purchase common stock	4,317,437	3,062,478
Shares subject to warrants to purchase common stock	1,938,143	960,117
Total	7,097,247	17,312,415

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	May 11, 2021	Apr. 30, 2021	Apr. 15, 2021
Subsequent Events (Details) [Line Items]
Lease term			40 months
Base rent			$ 14,000
Security deposit			$ 47,000
Purchase of stock	395,000	395,000